Company History

From a research concept to a clinical-stage biotech company (with Phase 1 study completed for dapagliflozin transdermal program), Biotts’ journey reflects sustained progress in transdermal drug delivery science, strategic partnerships, and intellectual property development. Founded in 2018 to solve a fundamental challenge – delivering large-molecule therapeutics through the skin – the company has evolved into a GMP-certified operation with an expanding international patent portfolio and a pipeline advancing toward clinical validation.

Timeline

2018 – Foundation
Biotts founded in Wrocław, Poland by co-founders Dr. Paweł Biernat, Dr. Jan Meler, and Konrad Krajewski to develop the proprietary MTC-Y™ transdermal carrier platform.

2019 – Patent Applications Filed
Core patent application for MTC-Y carrier technology filed in Poland (priority date January 10, 2019), establishing intellectual property foundation. Additional patent applications filed for local anesthetics carrier modification and direct tabletting process. International patent family expanded with filings in Canada, USA, Europe, Japan, Brazil, China, and India.

2020 – Early Funding & Partnerships
Secured public grant from NCBiR Fast Track with over PLN 11.2 million in funding alongside private equity funding from Leonarto VC and Montis Capital. Initiated preclinical studies demonstrating transdermal delivery of over 6000 Da molecules, including peptides.

2021 – Industry Recognition
Technology and business model recognized by Deloitte Technology Fast 50 Central Europe (“Impact Star” Award), validating both scientific innovation and commercial potential.

2022 – Infrastructure & GMP Implementation
Relocated to expanded ~350 m² facility in Bielany Wrocławskie. Initiated GMP implementation in laboratory and production areas. Established strategic partnership with Servier for advanced formulation development. Completed preclinical validation for insulin and GLP-1 peptides, demonstrating sustained delivery in animal models.

2023 – Clinical Entry & IP Expansion
Core patent for MTC-Y technology granted in Canada. Completed Phase 1 clinical study for dapagliflozin transdermal patch in 30 healthy volunteers, demonstrating safety, tolerability, and favorable pharmacokinetic profile with sustained delivery. GMP-certified R&D facility operational. Additional patent applications filed for GLP-1 peptides, long-acting insulin, and SGLT2 inhibitors. Collaboration agreement signed with Bioton S.A. (December).

2024 – Breakthrough Achievement & IP Milestones
Core patent for MTC-Y technology granted in Poland. Reported world-first achievement in Proof-of-Concept study with Bioton: successful transdermal delivery of insulin, demonstrating 55% bioavailability and 5-day sustained release in preclinical models (April). This milestone confirmed MTC-Y™ platform’s capability to deliver large-molecule biologics through intact skin.

2025 – Clinical Advancement & US Patent Grant
US patent granted for transdermal formulation developed with MTC-Y platform (January). Regulatory pathway established via hybrid approval route (EU Article 10(3) / US 505(b)(2)). Patent portfolio now includes granted patents in Poland, Canada, and USA, with additional approvals pending in Europe, Japan, Brazil, China, and India across multiple patent families.
Preparing first-in-human (FIH) Phase 1 clinical study for transdermal insulin (MTC-INS).